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Development of antibody protection during SARS-CoV-2 infection is a pressing question for
public health and for vaccine development. We developed highly sensitive SARS-CoV-2-
specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid
protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+
subjects (n= 115) and were absent in the negative controls. Other isotype antibodies (IgA,
IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and
convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lenti-
viruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had
up to 3000-fold higher antibody and neutralization titers compared to outpatients or con-
valescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs
against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high
specificity and sensitivity of our assays, which may impact understanding the quality or
duration of the antibody response during COVID-19 and in determining the effectiveness of
potential vaccines.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused the COVID-19 pandemic, enterstarget cells through the interaction of its envelope spike
protein with the primary host cell receptor angiotensin-
converting enzyme-2 (ACE2), which is then cleaved by a serine
protease (TMPRSS2) to allow viral fusion and entry across the cell
membrane1. Antibodies that can bind to the spike protein have
the potential to neutralize viral entry into cells and are thought to
play an important role in the protective immune response to
SARS-CoV-2 infection2–11.
To predict protection against SARS-CoV-2, it is critical to
understand the quantity, quality and duration of the antibody
response during different stages of COVID-19 and in the con-
valescent period. In this regard, assessing the level of neutralizing
antibodies (NAbs) that block viral entry into cells could be a
critical parameter in determining protection from SARS-CoV-2
and management of convalescent plasma therapies, which are
being tested as a COVID-19 treatment option12–15. Defining the
relationship between disease severity, other individual-specific co-
morbidities and the NAb response will be critical in our under-
standing of COVID-19 and in tailoring effective therapies.
Currently available SARS-CoV-2 antibody tests mostly lack
sufficient dynamic range and sensitivity to allow for accurate
detection or determination of the magnitude of the antibody
response16. Furthermore, potential cross-reactivity among SARS-
CoV-2 specific antibodies to other endemic coronaviruses could
also be confounders in these tests17–20, thus making them less
reliable. Determining neutralization activity in patient plasma
also has challenges, as these assays generally rely on live virus
replication, requiring a high-level biohazard security BSL-3 level
laboratory. Therefore, there is an unmet need to develop sensitive
antibody and virus neutralization assays that are sufficiently
robust for screening and monitoring large numbers of SARS-
CoV-2 infected or convalescent subjects.
To overcome these experimental challenges, here we devel-
oped: (1) Highly sensitive bead-based fluorescent immunoassay
for measuring SARS-CoV-2 specific antibody levels and isotypes,
and (2) Robust SARS-CoV-2 spike protein pseudovirus to mea-
sure NAb levels in COVID-19 patient plasma. We found striking
differences in total antibody levels and neutralization titers
between hospitalized or severe COVID-19 patients relative to
outpatient or convalescent plasma donors, which were obtained
with the purpose of transfer to and treatment of patients. Sig-
nificant correlations between antibody levels and neutralization
titers, age and NAbs to SARS-CoV were also observed. These
assays and findings have important implications for assessing the
breadth and depth of the humoral immune response during
SARS-CoV-2 infection and for the development of effective
antibody-based therapies or vaccines.
Results
Development of SARS-CoV-2 specific antibody assay. Deter-
mining antibody response in SARS-CoV-2 infected subjects
remains challenging, due to lack of sufficient dynamic range to
determine precise antibody titers with antibody isotypes simul-
taneously. To overcome these obstacles, we developed a fluor-
escent bead-based immunoassay that takes advantage of the high
dynamic range of fluorescent molecules using flow cytometry
(Fig. 1a). In this assay, we immobilized biotinylated SARS-CoV-2
spike protein receptor-binding domain (RBD) or the Nucleo-
protein (N) on streptavidin beads to detect specific antibodies
from patient plasma (Fig. 1a). Different antibody isotypes were
measured using anti-Ig (IgG, IgA, IgM, IgG1-4) specific second-
ary antibodies conjugated to a fluorescent tag (Fig. 1a). Using
either anti-S-RBD antibody or soluble ACE2-Fc, we show very
high sensitivity in detecting spike protein binding, down to
picogram ranges (Fig. 1b). Similarly, S-RBD-specific antibodies
were detectable in serial dilutions up to 100,000-fold of plasma
samples from SARS-CoV-2 PCR+ subjects at high specificity and
sensitivity (Fig. 1c). We then used the titration curves from
COVID-19 convalescent and healthy control plasma to normalize
the area under the curve (AUC) values to quantitate the antibody
levels (Supplementary Fig. 1a). Negative threshold values were set
using healthy control AUC levels plus one standard deviation of
the mean.
In addition to S-RBD and Nucleocapsid protein, we also
attached different viral components such as S1 subunit of spike
protein, S1 subunit N terminal domain (NTD) and S2
extracellular domain (ECD) onto the magnetic beads and tested
IgG levels specific to those viral proteins to compare the antibody
levels they detect. Interestingly, S-RBD captured significantly
more antibodies compared to S1, which is the subunit of spike
protein that contains S-RBD (p= 0.0356) (Fig. 1d).
We also evaluated the dynamic range of our assay by screening
some of the plasma samples with a commercial ELISA-based
antibody assay next to our bead-based assay and comparing the
detected antibody levels. Antibody levels from the two antibody
assays showed a high correlation (rs= 0.86), confirming our
assay’s precision, and the bead-based antibody assay showed a
wider dynamic range compared to the ELISA-based assay
(Fig. 1e).
Using the bead-based assay, we screened COVID-19 patient or
convalescent plasma samples (Table 1; n= 115) for total S-RBD
and Nucleocapsid specific IgG AUC values of COVID-19 positive
subjects, which varied 3-logs from ~104 to ~107 (Fig. 2a). S-RBD-
specific IgM (40/40) and IgA (115/115) were also detectable and
above the negative control threshold in all subjects (Fig. 2a).
Statistical sensitivity and specificity estimates of our bead-based
antibody assays were 100% and 99.34% for S-RBD IgG; 100% and
90.9% for S-RBD IgM; 94.26% and 87.87% for S-RBD IgA and
99.13% and 94.93% for Nucleocapsid IgG, respectively. Further-
more; S1 subunit, S1 N terminal domain (NTD), S2 extracellular
domain (ECD) and Nucleocapsid protein-specific IgG and S-
RBD-specific IgA levels positively correlated with S-RBD IgG
antibodies (Supplementary Fig. 1b, c) with the highest correlation
with S1 IgG (rs= 0.987). Notably, IgG1 subclass antibody levels
were comparable to total IgG levels whereas the other subtypes
were relatively lower (Fig. 2b). There were significant differences
in S-RBD or Nucleocapsid antibody levels between outpatient,
hospitalized, and intensive care unit (ICU)/deceased subjects,
with the highest levels observed in the most severe cases
(Fig. 2c–e). Importantly, subjects who had recovered from
COVID-19 and were also potential donors for convalescent
plasma therapy (hereafter referred to as plasma donors), also had
significantly lower antibody titers than hospitalized, ICU or
deceased patients (Fig. 2c–e). Overall, individual S-RBD and
Nucleocapsid IgG levels appeared to correlate with their IgA and
IgG subclass (IgG1-4) responses to S-RBD (Supplementary
Fig. 1d). Subdividing the subjects by sex did not reveal any
statistical difference in IgG levels at any of the disease stages
(Fig. 2f).
Development of SARS-CoV-2 spike-protein pseudovirus. Next,
we sought to develop a sensitive and high-throughput SARS-
CoV-2 neutralization assay by incorporating SARS-CoV-2 spike
protein into lentiviruses to assess specific inhibition of viral entry.
To produce spike protein pseudotyped lentiviral particles, we first
ensured expression of the spike protein on the cell membrane of
transfected 293 cells, from which it would incorporate into the
lentiviruses. Human codon-optimized SARS-CoV-2 spike protein
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sequences with and without endoplasmic reticulum retention
signal (ERRS), which would be predicted to be more efficiently
expressed on the cell surface membranes, were cloned into an
expression vector and transfected into 293 cells. To evaluate
membrane expression of spike protein, cells were stained with
recombinant soluble ACE2-Fc fusion protein followed by a sec-
ondary staining with an anti-Fc antibody (Fig. 3a). The percen-
tages of spike protein over-expressing cells were similar in the
presence or absence of ERRS, but cells expressing spike protein
without ERRS showed a higher geometric mean of expression
(Fig. 3b). As such, we used spike protein lacking the ERRS for
lentiviral pseudotyping to ensure its higher incorporation onto
viral membranes.
We then co-transfected 293 cells with replication-defective
lentivectors encoding GFP or RFP reporter genes and the spike
protein-encoding plasmid and harvested the supernatant at 24 h,
which was then used to infect cells expressing ACE2 (Fig. 3c).
Bald particles were generated by transfecting lentivirus plasmids
Fig. 1 SARS-CoV-2 specific antibody detection assay. a Illustration of antibody detection assay. Biotinylated S-RBD or Nucleocapsid proteins are captured
by streptavidin-coated beads, then incubated with plasma samples and stained with PE-conjugated anti-IgG, IgA, IgM, IgG1, IgG2, IgG3, IgG4 antibodies.
Fluorescence intensity analyzed by flow cytometry. b Histogram overlays demonstrating the detection of anti-S-RBD human IgG antibody (left) and soluble
ACE2-Fc (right) as positive controls for plasma antibody assay. c Representative patient plasma titration. Healthy control plasma at 1:100 dilution was
used as a negative control. Serial dilutions were used in the flow cytometry overlay. d Comparison of IgG antibody levels captured by S-RBD, S1 subunit of
spike, S1 N terminal domain (NTD), S2 extracellular domain (ECD) and nucleocapsid protein coated beads (n= 46 biologically independent samples).
e Correlation and comparison of bead-based assay S-RBD IgG antibody levels with ELISA-based assay (n= 44). Two-tailed Mann–Whitney U test was
used to determine the statistical significance in (d) and two-tailed Spearman’s was used for correlation significance in (e). Horizontal bars in (d) and
(e) indicate mean values.
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without any envelope and used as a negative control. Next, we
tested the transduction efficiency of the viruses on wild-type 293
cells, given they express low levels of endogenous ACE2
(Supplementary Fig. 2a, b). While we found clearly defined
infection of 293 cells with spike-protein pseudovirus compared to
bald virions, infection rate determined by GFP or RFP expression
was relatively low (Fig. 3d). We therefore generated human-ACE2
over-expressing 293 cells with a GFP reporter (ACE2-IRES-GFP)
or fused to fluorescent mKO2 protein (ACE2-mKO2). ACE2
overexpression of ACE2-IRES-GFP or ACE2-mKO2 was con-
firmed by staining with SARS-CoV-2 spike-protein S1 subunit
fused with mouse Fc (mFc) and anti-mFc secondary antibody
(Supplementary Fig. 2a, b). Indeed, these ACE2 over-expressing
293 cells (293-ACE2) were efficiently transduced with spike
protein pseudoviruses encoding either GFP or RFP (Fig. 3e). The
efficiency of spike-protein pseudovirus infection was comparable
in ACE2-IRES-GFP or ACE2-mKO2 fusion protein (Fig. 3e), and
therefore both were used in subsequent neutralization experi-
ments. In addition, we developed SARS-CoV spike protein
pseudotyped lentivirus, which similarly infected 293-ACE2 cells
at almost 100% efficiency at higher virus supernatant volumes
(Fig. 3f). We also tested the stabilities of SARS-CoV-2 and SARS-
CoV spike protein pseudotyped lentiviruses after serial freeze/
thaw cycles and found that their infectivity remained mostly
similar with little loss of activity after 3 cycles (Fig. 3f).
Neutralization of SARS-CoV-2 spike-protein pseudovirus with
soluble ACE2, NAbs, and COVID-19 plasma. We next inves-
tigated whether spike protein pseudoviruses could be neutralized
by soluble ACE2 (sACE) or spike protein-specific NAbs (Fig. 4a).
For this experiment, spike protein pseudotyped SARS-CoV-2 and
SARS-CoV pseudoviruses were pre-cultured with different con-
centrations of sACE2 or NAbs, then added to 293-ACE2 cells.
Subsequently, the infection levels were determined 3 days post-
infection based on GFP or RFP expression as described above.
sACE2 neutralized both SARS-CoV-2 and SARS-CoV pseudo-
virus infections in a dose-dependent manner (Fig. 4b, c), although
neutralization of SARS-CoV-2 was slightly better than that of
SARS-CoV pseudoviruses (Fig. 4b, c, and Supplementary Fig. 3a).
Furthermore, spike-RBD-specific NAb neutralized SARS-CoV-2
pseudovirus entry much more efficiently than sACE2 but had no
effect on SARS-CoV pseudovirus (Fig. 4c). One of the SARS-
CoV-2 S-RBD-specific antibodies (non-NAb) did not show any
neutralization of SARS-CoV-2, however very low-level neu-
tralization of SARS-CoV pseudovirus was detected (Fig. 4c). We
also observed measurable differences in the neutralizing activity
of four different NAbs and two different soluble ACE2 proteins
from different sources (Fig. 4d), showing the utility of this assay
for such screening. Taken together, these experiments demon-
strate that the combination of pseudotyped viruses and 293-
ACE2 cells can be used to generate highly sensitive SARS-CoV-2
and SARS-CoV neutralization assays.
Using this approach, we then tested neutralization titers from
COVID-19 patients or seropositive donors with a serial dilution
of their plasma. Accordingly, plasma samples in threefold serial
dilutions were incubated with spike pseudovirus and added to
293-ACE2 cells and infection was determined as described in
Fig. 4. Healthy control plasma samples were used as negative
controls whereas anti-S-RBD NAb served as a positive control
(Fig. 5a). None of the control plasma (n= 34, 1 shown in Fig. 5a)
tested showed any neutralization activity, whereas patient plasma
efficiently neutralized the virus at up to 10,000-fold serial dilution
(Fig. 5a). The 50% neutralization titer (NT50) was determined
using the half-maximal inhibitory concentration values of plasma
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Fig. 2 SARS-CoV-2 specific antibody detection in COVID-19 and convalescent plasma samples. a Measurement of spike protein and nucleocapsid
protein-specific IgG and spike protein-specific IgM and IgA antibodies as described in Fig. 1. Area under the curve (AUC) values of plasma antibodies were
calculated from reciprocal dilution curves in antibody detection assay (n= 256 for S-RBD IgG and Nucleocapsid IgG, n= 50 for S-RBD IgM, n= 144 for
S-RBD IgA). Dotted lines indicate the negative threshold calculated by adding 1 standard deviation to the mean AUC values of healthy controls’ plasma.
Horizontal bars show the mean value. Green, blue, salmon, red and yellow dots indicate negative controls, outpatient, hospitalized, ICU/deceased and
plasma donor subjects, respectively. b S-RBD-specific IgG subclass AUC levels (n= 144 for S-RBD IgG1, n= 74 for S-RBD IgG2, S-RBD IgG3 and S-RBD
IgG4) c S-RBD IgG AUC values of subject plasma grouped by outpatient, hospitalized, ICU or deceased and plasma donors (n= 115) d Nucleocapsid
protein IgG AUC values of subject plasma grouped by outpatient, hospitalized, ICU or deceased and convalescent plasma donors (n= 115). e S-RBD IgA
AUC values of subject plasma grouped by outpatient, hospitalized, ICU or deceased and plasma donors (n= 115). f S-RBD IgG AUC values of severity
groups and plasma donors subdivided into males and females (n= 115). Green dots show female subjects while purple squares indicate male subjects.
Statistical significances were determined using two-tailed Mann–Whitney U test.
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Fig. 3 Development of SARS-CoV-2 and SARS-CoV spike-protein pseudotyped lentiviruses. a Schematic illustration of spike protein expression on the
cell surface and soluble ACE2-Fc staining followed by an anti-Fc antibody staining. b 293 cells transfected with spike protein with or without endoplasmic
reticulum retention signal (ERRS) or with VSV-G as a negative control. The cells were stained with ACE2-Fc and anti-Fc-APC secondary antibody, flow
cytometry data overlays are shown. c Schematic representation of spike protein pseudovirus generation and subsequent infection of ACE2-expressing host
cells. A lentivector plasmid and a spike protein over-expressing envelope plasmid are used to co-transfect 293 cells to generate spike pseudovirus that in
turn infect engineered cells over-expressing wild-type ACE2 or ACE2-mKO2 fusion. d Infection of wild-type 293 cells with either bald lentiviruses
generated without envelope plasmid or spike protein pseudovirus. e Infection of 293-ACE2 cells with bald and spike lentiviruses. GFP and mKO2 markers
are used to determine ACE2 over-expressing cells in ACE2-IRES-GFP and ACE2-mKO2, respectively. f The titrations of SARS-CoV-2 and SARS-CoV spike
protein pseudoviruses encoding RFP. Triangles and circles represent SARS-CoV and SARS-CoV-2 data, respectively. Brown, red, salmon and orange-
colored lines show direct infection, first, second and third freeze/thaw cycles, respectively. ACE2-IRES-GFP expressing 293 cells were incubated with
threefold serial dilutions of virus supernatant, stored for several hours at 4 °C or serially frozen and thawed for 1, 2 and 3 cycles, and analyzed for RFP
expression by flow cytometry on day 3 post-infection. Percent infection is % RFP+ cells after gating on GFP+ cells (i.e., ACE2+). Titration experiments
were replicated twice except for the ‘1 freeze/thaw cycle’ for which titrations were replicated four times. Error bars represent 1 standard deviation of mean
values.
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dilutions. Importantly, the NT50 values of the subjects were
much higher in hospitalized patients than in outpatients (Fig. 5b).
NT50 values for hospitalized and ICU/deceased subjects were also
up to 1000-fold higher than convalescent plasma donors (Fig. 5b).
Hospitalized males and females, separately, also remained higher
in their NT50 levels and no difference was observed within each
group (Fig. 5c).
We also tested whether SARS-CoV-2 PCR+ plasma could
neutralize the SARS-CoV pseudovirus. In total, 104 plasma
samples from all groups were tested for their ability to neutralize
Fig. 4 Neutralization of SARS-CoV-2 and SARS-CoV pseudoviruses with soluble ACE2 and Nabs. a Illustration of spike-protein pseudovirus blocked by
soluble ACE2 or neutralizing antibodies. b SARS-CoV-2 and SARS-CoV pseudovirus neutralization with soluble ACE2. SARS-CoV-2 RFP and SARS-CoV
GFP pseudoviruses were pre-incubated with soluble ACE2 for 1 h and added to 293 cells expressing ACE2-IRES-GFP or ACE2-mKO2 fusion, respectively.
c Neutralization of SARS-CoV-2 and SARS-CoV with S-RBD-specific antibodies and soluble ACE2 (sACE2). Viruses were pre-incubated with antibodies
(NAb#1 and SARS-CoV-2 S-RBD non-NAb) or soluble ACE2 (sACE2) proteins for 1 h at the concentrations shown and subsequently added to target cells.
Expression of RFP was determined at day 3 post-infection. Infection percentages were normalized to negative controls which are the infection conditions
with no blocking agent. Triangles and circles represent SARS-CoV and SARS-CoV-2 data, respectively. Red, green, blue and turquoise colored lines show
SARS-CoV-2 S-RBD NAb#1, SARS-CoV-2 S-RBD non-NAb, soluble ACE2 #1 and #2, respectively. d Neutralization of SARS-CoV-2 pseudoviruses using 4
different S-RBD NAbs and two different soluble ACE2 proteins. NAb #1 and #4 were human antibodies whereas NAb #2 and #3 were mouse. Red lines
represent antibodies while blue lines show soluble ACE2 molecules. Dot, triangle, square, asterisk, circle and star symbols indicate SARS-CoV-2 S-RBD
NAb #1, #2, #3, #4, soluble ACE2 #1 and #2, respectively. Graphs in (c) and (d) represent three replicates of the experiments. Error bars indicate one
standard deviation of mean values.
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Fig. 5 Neutralizing titers for SARS-CoV-2 and SARS-CoV in COVID-19 subject plasma. a Neutralization assay with S-RBD-specific NAb, healthy control
plasma, and a COVID-19 patient plasma. Threefold serial dilutions of NAb from 10 μg/ml to 1 ng/ml or the plasma from 1:10 to 1:10,000 were pre-
incubated with spike protein pseudovirus and added to 293-ACE2 cells. GFP expression was analyzed by flow cytometry 3 days post infection. b SARS-
CoV-2 neutralization titers (NT50) of COVID-19 plasma grouped as an outpatient, hospitalized, ICU or deceased and convalescent plasma donor groups
(n= 113). c NT50 of COVID-19 patient and plasma donor groups subdivided into males and females (n= 113). d Comparison of NT50 of COVID-19 plasma
for SARS-CoV-2 and SARS-CoV neutralization. SARS-CoV-2 or SARS-CoV pseudoviruses were pre-incubated with COVID-19 plasma from all severity
groups (n= 104), 293-ACE2 cells were infected and RFP expression was determined at day 3 using flow cytometry. e Graph of SARS-CoV-2 NT50 values
from hospitalized subjects plotted against SARS-CoV (n= 46). Two-tailed Mann–Whitney U test was used to determine the statistical significances in
figures (b), (c) and (d) and two-tailed Spearman’s was used for figure (e). Horizontal bars in (b), (c) and (d) indicate mean values.
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SARS-CoV-2 and SARS-CoV pseudoviruses. Remarkably, most of
the plasma samples also neutralized SARS-CoV pseudovirus,
although less efficiently than SARS-CoV-2 pseudovirus (Fig. 5d).
Interestingly, NT50 levels of plasma samples for SARS-CoV-2
and SARS-CoV significantly correlated in hospitalized subjects
(Fig. 5e), whereas there were no correlations in outpatients and
plasma donors or when all groups were combined (Supplemen-
tary Fig. 5a). In addition, when we compared the severity groups
for their SARS-CoV NT50 values, we did not observe any
significant difference between the groups (Supplementary
Fig. 5b).
Correlations of SARS-CoV-2 neutralization, antibody levels,
and COVID-19 subject characteristics. To better understand the
associations between patient characteristics and the humoral
immune response in COVID-19, we next determined correlations
between antibody AUC levels, NT50 values and demographics of
the study subjects. First, we assessed the correlation between
NT50 values with S-RBD or Nucleocapsid antibody titers or their
subclasses. All Igs including S-RBD IgG (rs= 0.81), Nucleocapsid
IgG (rs= 0.689), S-RBD IgA (rs= 0.60) and S-RBD IgM (rs=
0.47) showed significant correlation with NT50 values of each
subject (Fig. 6a). Among Ig subclasses specific to S-RBD; IgG1
(rs= 0.80), IgG3 (rs= 0.69) and IgG2 (rs= 0.67) and, to a lesser
degree, IgG4 (rs= 0.51) also correlated with NT50 values
(Fig. 6b). Total S-RBD IgG also correlated in a similar fashion
with other IgG isotypes, with IgG1 showing the highest positive
correlation (rs= 0.96) (Supplementary Fig. 4a).
Next, we correlated the antibody AUC levels and NT50 values
of the subjects with their age. Subjects had significantly higher
S-RBD IgG (rs= 0.53), nucleocapsid IgG (rs= 0.43), S-RBD IgA
(rs= 0.41) and NT50 (rs= 0.579) values, as their age increased
(Fig. 6c).
We also explored the relationship of the number of days
between PCR test result and blood draw with antibody levels or
NT50 values, excluding the subjects that had 15 days or fewer
between those dates to ensure that antibody levels had already
reached their peak. Of note, there was no correlation between the
number of days and the IgG to S-RBD or the NT50
(Supplementary Fig. 4b), suggesting a potential persistence in
antibody titers at least for the 3-month duration in this cohort.
Discussion
The COVID-19 pandemic is continuing to spread globally una-
bated, including within the United States. There is an urgent need
to better understand the immune response to the virus so that
effective immune-based treatments and vaccines can be
developed21,22. Neutralization of the virus by antibodies (NAbs)
is one of the goals to achieve protection against SARS-CoV-223.
Despite the rapid development of many serological tests,
important questions about the quality and quantity of ser-
oprevalence in individuals still remain unclear24,25. Here, we
Fig. 6 Correlations of antibody, neutralization levels and COVID-19 subject characteristics. a Neutralization (NT50) of COVID-19 plasma correlated
with S-RBD IgG (n= 113), S-RBD IgA (n= 113), S-RBD IgM (n= 40), and nucleocapsid IgG (n= 113). b Correlation of NT50 with S-RBD-specific IgG
subclasses; IgG1 (n= 113), IgG2 (n= 74), IgG3 (n= 74), and IgG4 (n= 74). c Correlation of S-RBD IgG (n= 115), nucleocapsid IgG (n= 115), S-RBD
IgA (n= 115), and NT50 (n= 113) with age. Two-tailed Spearman’s was used to determine statistical significances.
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developed highly sensitive and specific humoral assays that
measure both the magnitude and neutralization capacity of
antibody responses in COVID-19 patients. Every SARS-CoV-2
infected subject we tested (n= 115) had detectable antibodies and
all subjects except one exhibited neutralization; both of these
qualities were completely absent in non-infected controls. How-
ever, there was a profound difference in antibody and neu-
tralization titers among subjects, ranging in more than 1000-fold
differences. Furthermore, we found that almost all COVID-19
patients also had NAbs for SARS-CoV, suggesting a high degree
of cross-reactivity between the spike proteins of these two viruses.
One of our key findings was clustering of antibody responses
based on the severity of the disease; as hospitalized patients
showed much higher antibody levels and neutralization capacity
than outpatient subjects or convalescent plasma donors. This
finding is consistent with recent reports suggesting that patients
with more severe disease contain relatively higher levels of anti-
bodies for SARS-CoV-2 infection2,26–30. Interestingly, most of the
convalescent plasma donors had much lower levels of NAbs (by
at least an order of magnitude) than hospitalized patients, who
would be the suitable recipients for such plasma transfer therapy.
This finding raises the question of whether convalescent plasma
transfers may actually provide benefit to severe COVID-19
patients by providing NAbs. It may perhaps be more beneficial to
identify donors with much higher NAb titers for the plasma
donation. As such, our findings point to the importance of having
access to assays that have a large dynamic range to detect anti-
body responses in COVID-19 patients or seropositive individuals.
This neutralization assay also revealed differences in commercial
antibodies to SARS-CoV-2 in their capacity to block virus entry,
and as such can be used for rapid identification or generation of
synthetic NAbs. In addition to measuring neutralization titers, the
pseudoviruses can be used to probe cells that have the potential to
be infected with SARS-CoV-2, given lentiviruses can infect most
cell types and do not require cell division to integrate into the
genome. This infection assay may also be used to screen small
molecules that may impact virus cell entry.
Along with SARS-CoV-2, we also developed a pseudotyped
lentivirus with SARS-CoV spike protein, which was equally effi-
cient at infecting ACE2 overexpressing cells. This finding is
consistent with results that SARS-CoV-2 spike protein in com-
plex binding with human ACE2 (hACE2) is similar overall to that
observed for SARS-CoV31. There was however slightly better
neutralization of SARS-CoV-2 cell entry than SARS-CoV with
soluble ACE2, which could be due to key residue substitutions in
SARS-CoV-2, creating a slightly stronger interaction and thus
higher affinity for receptor binding than SARS-CoV spike pro-
tein31. Accordingly, we also tested the ability of COVID-19
patient plasma for SARS-CoV neutralizing capacity and found
significant SARS-CoV specific neutralization in COVID-19
patients. However, the neutralization titers for SARS-CoV were
significantly lower and there was no correlation with the neu-
tralization activity against SARS-CoV-2 when all severity groups
were combined. Indeed, some donors even had relatively higher
SARS-CoV neutralization (Fig. 5e). Further, there was a sig-
nificant correlation between SARS-CoV-2 and SARS-CoV NT50
levels when hospitalized and ICU/deceased subjects were ana-
lyzed separately. Given that the two viruses share ~75% identical
amino acid sequences in their spike proteins and there are con-
served epitopes between them32, it is conceivable that some of the
SARS-CoV-2 NAbs have cross-neutralizing activity33,34. It is
noteworthy that a recent study showed a NAb developed for
SARS-CoV was highly effective at neutralizing SARS-CoV-235.
It is also tempting to speculate that presence of SARS-CoV spe-
cific NAbs could be more potent perhaps by targeting highly
conserved regions of the spike protein, making it more difficult
for the virus to select for escape mutants.
Other antibodies and neutralization assays have been devel-
oped during the submission of our manuscript2,3,9,36–40.
Although direct comparison is difficult due to differences in the
assay methodologies and different sample sets, we believe our
assays embody distinctive features that further enhance this cri-
tically important immune response to SARS-CoV-2. The use of
the flow cytometry bead-based fluorescent system that detects
spike or Nucleocapsid protein-bound antibodies provides a high-
throughput assay with a very high dynamic range and sensitivity,
as it could detect antibodies from some subjects at up to a
million-fold dilution of the plasma. This assay is also scalable and
can be easily adaptable to other viral antigens. Using a flow
cytometry platform is also important in that the assay can be
further developed in a single panel to identify all antibody iso-
types simultaneously and to complement flow cytometric
immune phenotyping of COVID-19 patients. The high sensitivity
and specificity of our assay has allowed us to correlate the spike
protein RBD-specific antibody levels with neutralization titers,
which showed very high concordance, and thus can be utilized as
a proxy for neutralization in a clinical setting. Furthermore, the
bead-based immunoassay can also be further developed to screen
for antibodies reacting to other SARS-CoV-2 antigens simulta-
neously and can be useful in identifying antibodies that cross-
react between different species of coronavirus proteins. Deter-
mining other isotypes such as IgA and IgG subclasses may also
help in future mechanistic studies. It is clear that the dominant
antibody response in almost all donors was IgG1, but some also
show high IgA and IgG2-4, at varying levels. For example, given
the importance of IgA antibodies in providing immunity on
mucosal surfaces within the respiratory system, SARS-CoV-2
RBD-spike protein-specific IgA levels may also play an important
role in the upper and lower respiratory system, or perhaps also in
the gut, of COVID-19 patients41,42.
There are also several potential practical implications for our
findings. First, the patient population with the greatest risk fac-
tors for severe outcomes from infection such as age and co-
morbid conditions had the highest antibody titers as well as
neutralization of the virus. This is also the case for those patients
who had a lethal disease. It is therefore possible that surviving
COVID-19 may require non-antibody-dependent factors or that
producing too much antibody may even have deleterious
effects43, such as potential antibody-dependent enhancement
phenomenon by triggering Fc receptors on macrophages44. In
this regard, it is interesting to note that a Bruton tyrosine kinase
inhibitor that targets Fc-receptor signaling in macrophages is
being tested in a randomized clinical trial45. Thus, understanding
the mechanism of survival from COVID-19 and immune
response dynamics will be critical in the better prediction of
outcomes as well as in assaying for a protective response to
potential vaccines.
In conclusion, the assays developed herein can have utility in
uncovering dynamic changes in the antibody levels in SARS-
CoV-2 infected subjects over time, in responses to vaccines and as
potential clinical determinants for plasma or antibody therapies
for COVID-19 patients.
Methods
Participants. We enrolled 69 female and 46 male COVID-19 subjects with an
average age of 54 and 51, respectively. The subjects (n= 115) were recruited at
SUNY Downstate Medical Center, New York, NY, Cedars Sinai, Los Angeles, CA,
or the University of Connecticut, School of Medicine, Farmington CT following
testing and/or admission for COVID-19 infection. Written informed consent was
obtained from all participants in this study and was approved by the following
IRBs: (1) IRB# SUNY:269846. The patients were recruited at SUNY Downstate, NY
and processed and biobanked at Amerimmune, Fairfax VA; (2) IRB#
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STUDY00000640. Convalescent plasma was collected at Cedars Sinai Medical
Center according to FDA protocol (https://www.fda.gov/vaccines-blood-biologics/
investigational-new-drug-ind-or-device-exemption-ide-process-cber/
recommendations-investigational-covid-19-convalescent-plasma#Collection%20of
%20COVID-19). The source of the convalescent plasma was volunteer blood
donors who were recovered from COVID-19. Donors met routine blood donor
eligibility requirements established by the FDA and had a prior SARS-CoV-2
infection documented by a laboratory test for the virus during illness, or antibodies
to the virus after recovery of suspected disease. All donors were at least 28 days
from either resolution of COVID-19 symptoms or diagnostic clearance, whichever
was longer; (3) IRB# 20-186-1. UConn Healthcare workers who tested positive for
the virus by PCR were recruited and samples banked for future testing. (4) IRB#:
17-JGM-13-JGM or 16-JGM-06-JGM. De-identified control subjects (n= 56) with
previously frozen (more than a year ago) samples obtained from healthy controls
or determined to be SARS-CoV-2 PCR negative (IRB SUNY:269846). All antibody
assays were performed at the Jackson Laboratory for Genomic Medicine, Farm-
ington, CT. Subject characteristics are shown in Table 1. All plasma samples were
aliquoted and stored at −80 °C. Prior to experiments, aliquots of plasma samples
were heat-inactivated at 56 °C for 30 min.
Over-expression of SARS-CoV-2 spike protein and cell culture. Human codon-
optimized SARS-CoV-2 spike-protein sequence was synthesized by Molecular-
Cloud (MC_0101081). 5′-ACGACGGAATTCATGTTCGTCTTCCTGGTCCTG-3′
and 5′-ACGACGGAATTCTTAACAGCAGGAGCCACAGC-3′ primers were used
to amplify the SARS-CoV-2 spike protein sequence without ERRS that is the last 19
amino acids33. Full length and truncated SARS-CoV-2 spike-protein sequences were
then cloned into pLP/VSVG plasmid from Thermo Fisher under CMV promoter
after removing the VSVG sequence via EcoRI-EcoRI restriction digestion. HEK-
293T cells (ATCC; mycoplasma-free low passage stock) were transfected with the
expression plasmids using Lipofectamine 3000 (Invitrogen) according to the man-
ufacturer’s protocol. The cells were cultured in complete RPMI 1640 medium
(RPMI 1640 supplemented with 10% FBS; Atlanta Biologicals, Lawrenceville, GA),
8% GlutaMAX (Life Technologies), 8% sodium pyruvate, 8% MEM vitamins, 8%
MEM nonessential amino acid, and 1% penicillin/streptomycin (all from Corning
Cellgro) for 72 h46. The cells were then collected using %0.05 Trypsin-0.53mM
EDTA (Corning Cellgro) and stained with Biotinylated Human ACE2/ACEH
Protein, Fc,Avitag (Acro Biosystems) then stained with APC anti-human IgG Fc
Antibody clone HP6017 (Biolegend). Samples were acquired on a BD FAC-
Symphony A5 analyzer and data were analyzed using FlowJo (Tree Star).
Pseudotyped lentivirus production and titer measurement. Lentivector plas-
mids containing RFP or GFP reporter genes were co-transfected with either SARS-
CoV-2 spike protein or SARS-CoV spike protein (Human SARS coronavirus
(SARS-CoV) spike glycoprotein Gene ORF cDNA clone expression plasmid
(Codon Optimized) from SinoBiological) plasmids into HEK-293T cells using
Lipofectamine TM 3000 (Invitrogen) according to the manufacturer’s protocol.
Viral supernatants were collected 24–48 h post-transfection, filtered through a
0.45 μm syringe filter (Millipore) to remove cellular debris, and concentrated with
Lenti-X (Invitrogen) according to the manufacturers' protocol. Lentivirus super-
natant stocks were aliquoted and stored at −80 °C. To measure viral titers, virus
preps were serially diluted on ACE2 over-expressing 293 cells. Seventy-two hours
after infection, GFP or RFP positive cells were counted using flow cytometry and
the number of cells transduced with virus supernatant was calculated as infectious
units/per mL.
Generating human ACE2 over-expressing cells. Wildtype ACE2 sequence was
obtained from Ensembl Gene Browser (Transcript ID: ENST00000252519.8) and
codon-optimized with SnapGene by removing restriction enzyme recognition sites
that are necessary for subsequent molecular cloning steps, preserving the amino
acid sequence. The sequence of mKO2 (monomeric Kusabira-Orange-247)
obtained from Addgene (#54625)48, and was added onto the C terminal of ACE2
proximal to the stop codon with a small linker peptide (ccggtcgccacc) encoding the
amino acids ‘PVAT’. The fusion constructs were synthesized via GenScript and
cloned into a lentiviral vector lacking a fluorescent reporter. The full-length
human ACE2 sequence without fusion fluorescent proteins was amplified from
the ACE2-mKO2 fusion construct using 5′-ACGACGGCGGCCGCATGTCAAG
CTCTTCCTGGC-3′ and 5′-ACGACGGAATTCTTAAAAGGAGGTCTGAACA
TCATCAG-3′ primers, generating a stop codon at the C-terminus, and then cloned
into a lentiviral vector encoding GFP reporter separated from multiple cloning site
via an internal ribosome entry site (IRES) sequence. To determine the virus titers,
HEK-293T cells were transduced with full-length ACE2-IRES-GFP, ACE2-mKO2
fusion construct lentiviruses and analyzed via flow cytometry for their reporter
gene expression 72 h after infection. Wild type and ACE2 over-expressing HEK-
293T were also stained with SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag (Acro
Biosystems) followed with APC Goat anti-mouse IgG2a Fc Antibody (Invitrogen).
Samples were acquired on a BD FACSymphony A5 analyzer and data were ana-
lyzed using FlowJo (BD Biosciences).
SARS-CoV-2 antibody detection using flow immunoassay. To screen for anti-
body binding to SARS-CoV-2 proteins, The DevScreen SAv Bead kit (Essen
BioScience, MI) was used. Biotinylated 2019-nCoV (COVID-19) spike protein
RBD, His, Avitag, Biotinylated CoV-2 (COVID-19) Nucleocapsid protein, His,
Avitag, Biotinylated CoV-2 (COVID-19) S1 protein, His,Avitag (Acro Biosystems,
DE), Biotinylated SARS-CoV-2 (2019-nCoV) Spike S1 NTD-His & AVI recom-
binant protein and Biotinylated SARS-CoV-2 (2019-nCoV) Spike S2 ECD-His
recombinant protein (Sino Biological Inc.) were coated to SAv Beads according to
manufacturer’s instructions. Confirmation of successful bead conjugation was
determined by staining with anti-His Tag (Biolegend) and flow cytometry analysis.
S-RBD, N, S1, S1-NTD, and S2-ECD conjugated beads were then used as capture
beads in flow immunoassay where they were incubated with anti-S-RBD human
IgG positive control (provided in GenScript SARS-CoV-2 Spike S1-RBD IgG &
IgM ELISA Detection Kit as positive control), recombinant Human ACE2-Fc
(Acro Biosystems) or plasma and serum samples for 1 h at room temperature.
Plasma samples were assayed at a 1:100 starting dilution and three additional
tenfold serial dilutions. Anti-S-RBD antibody and ACE2-Fc were both tested at a
5 μg/mL starting concentration and in additional fivefold serial dilutions. Detection
reagent was prepared using Phycoerythrin-conjugated anti-human IgG Fc clone
HP6017, anti-human IgM clone MHM-88 (Biolegend), anti-human IgA clone
IS11-8E10, anti-human IgG1 clone IS11-12E4.23.20 (Miltenyi Biotec), anti-human
IgG2 Fc clone HP6002, anti-human IgG3 Hinge clone HP6050, and anti-human
IgG4 pFc clone HP6023 (Southern Biotech), added to the wells and incubated for
another hour at room temperature. Plates were then washed twice with PBS and
analyzed by flow cytometry using iQue Screener Plus (IntelliCyt, MI). Flow cyto-
metry data were analyzed using FlowJo (BD biosciences). DevScreen SAv Beads
were gated using FSC-H/SSC-H, and singlet beads gate was created using FSC-A/
FSC-H. Gates for different DevScreen SAv Beads were determined based on their
fluorescence signature on RL1-H/RL2-H plot (on iQue plus). PE fluorescence
median, which is directly associated with each single plex beads was determined
using BL2-H (on iQue plus). Geometric means of PE fluorescence in different
titrations were used to generate the titration curve and 20 healthy control plasma
were used to normalize the AUC. Statistical analyses were performed using
GraphPad Prism 8.0 software (GraphPad Software).
SARS-CoV-2 antibody detection using ELISA. To evaluate antibodies binding to
CoV-2 S-RBD protein, SARS-CoV-2 Spike S1-RBD IgG and IgM ELISA Detection
Kit from GenScript was used according to the manufacturer’s instructions.
Absorbance was measured at 450 nm using an Epoch 2 microplate spectro-
photometer (BioTek).
Pseudotyped virus neutralization assay. Threefold serially diluted monoclonal
antibodies including anti-SARS-CoV-2 Neutralizing human IgG1 antibody from
Acro Biosystems, NAb#1 (Fig. 4c, d), GenScript clone ID 6D11F2, NAb#2 (Fig. 4d)
and GenScript clone ID 10G6H5, NAb#3 (Fig. 4d), Invitrogen clone ID MA5-
35939 Nab#4 (Fig. 4d), SARS-CoV-2 Spike S1-RBD IgG&IgM ELISA Detection Kit
non-neutralizing antibody (Fig. 4c), recombinant human ACE2-Fc (Acro Biosys-
tems, sACE2#1 and GenScript, sACE2#2 (Fig. 4d) or plasma from COVID-19
convalescent individuals and healthy donors have incubated with RFP-encoding
SARS-CoV-2 or GFP-encoding SARS-CoV pseudotyped virus with 0.2 multiplicity
of infection for 1 h at 37 °C. The mixture was subsequently incubated with 293-
ACE2 cells for 72 h after which cells were collected, washed with FACS buffer (1 ×
PBS+ 2% FBS) and analyzed by flow cytometry using BD FACSymphony A5
analyzer. Total cells were gated using FSC-A/SSC-A, GFP and RFP cell populations
were gated using GFP-A/PE-A. Cells that do not express GFP or RFP were used to
define the boundaries between positive and negative cell populations. To report the
percent infection in ACE2 positive cells, total cells were sub-gated on GFP+ and
RFP+ cell population was determined using PE-A.
Percent infection obtained was normalized for samples derived from cells
infected with SARS-CoV-2 or SARS-CoV pseudotyped virus in the absence of
plasma, ACE2-Fc or monoclonal antibodies. The half-maximal inhibitory
concentration for plasma (NT50), ACE2-Fc or monoclonal antibodies (IC50) was
determined using 4-parameter nonlinear regression (GraphPad Prism 8.0).
Statistics and reproducibility. All statistical analyses were performed using
GraphPad Prism V8 software. Continuous variable datasets were analyzed by the
Mann–Whitney U test for non-parametric datasets when comparing clinical
groups, and exact P values are reported. P < 0.05 was considered significant.
Spearman p analysis was used to determine the relationship existing between two
sets of non-parametric data, where a value of 0 indicated no relationship, values
between 0 and ±0.3 indicated a weak relationship, values between ±0.3 and ±0.7
indicated a moderate relationship, values between ±0.7 and ±1.0 indicated a strong
relationship, and a value of ±1.0 indicated a perfect relationship between sets of
data49. We report the result of all considered pairwise tests, and thus make no
formal adjustment for multiple comparisons. Numbers of repeats for each
experiment were described in the associated figure legends.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The source data for the Figures along with the Supplementary Figures presented in this
paper are available as Supplementary Data 1.
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